TL;DR
Get baking supplies delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Food Safety News publisher Bill Marler says he is asking the FDA, through two citizen petitions, to provide more identifying information in food outbreak disclosures. The supplied report says the petitions seek company names and location details, but the available text ends before describing the second petition or the FDA’s response.
Food Safety News publisher Bill Marler says he is asking the Food and Drug Administration to disclose more identifying details in food-safety outbreak information, including the companies and locations connected to investigations. In a publisher’s commentary, Marler describes two citizen petitions and argues that the requests follow transparency commitments already made by the Department of Health and Human Services and the FDA; the supplied report excerpt does not include the full petitions or the agency’s response.
Marler frames the petitions as a request to carry the FDA’s existing public statements about transparency into its handling of foodborne illness investigations. He points to HHS Secretary Robert F. Kennedy Jr.’s pledge of “radical transparency” and to FDA statements connecting transparency in food safety with reducing illness. Those commitments are documented statements; Marler’s view that they require the agency to publish additional outbreak details is his argument.
The specific disclosure gap he identifies is who was involved and where an outbreak occurred. Marler credits the FDA’s Executive Incident Summary abstracts for closed outbreak investigations as a step forward, but says they can omit company names and geographic details. The article cites prior reporting about an FDA mango-outbreak summary that did not identify a company, and a fatal Listeria investigation summary in which states were redacted.
Marler also recounts that Stop Foodborne Illness petitioned the FDA in February to stop treating company names as confidential. According to his account, the agency replied that the names were protected by the Trade Secrets Act. Marler says the legal issue has since been answered, but the supplied text ends before setting out that reasoning or explaining what the petitions ask the agency to do in full. The basis for that assertion cannot be independently assessed from the excerpt.
Names and Locations in Outbreak Reports
Identifying a company or location in an outbreak notice can help consumers make informed decisions about food they may have bought or eaten, and can help public-health agencies and businesses trace products. Without those details, the public may know an investigation occurred but have limited ability to connect it to a particular product or source. That is the practical issue at the center of Marler’s request.
Disclosure also involves competing interests. Company identification before an investigation is complete could affect businesses and consumers, while withholding details may limit the public’s ability to respond to a potential risk. The source excerpt describes the FDA’s reliance on the Trade Secrets Act in one earlier exchange, but does not provide the agency’s legal analysis, the petitions’ proposed safeguards, or a response to Marler’s current request. The dispute is therefore not only about a stated transparency goal; it also concerns what information the law permits the FDA to release and when.
Products Worth Considering
Instant Pot InstantChill Plus Ice Cream Maker, 2-Pint
Instant Pot Pro 8-Quart 10-in-1 Electric Pressure Cooker, Black
Instant Pot Duo 6-Quart 7-in-1 Electric Pressure Cooker
As an affiliate, we earn on qualifying purchases.
FDA Transparency Commitments on Food
The background Marler presents begins with Kennedy’s January 29, 2025, confirmation hearing. In remarks quoted in the article, Kennedy pledged transparency within HHS and said, “We should tell Americans when we don’t know.” He later described transparency as a condition for informed consent. These are statements attributed to Kennedy in the source, not an FDA rule requiring publication of particular outbreak details.
HHS and the FDA connected the phrase directly to food in a March 10, 2025, announcement about exploring changes to the self-affirmed Generally Recognized as Safe pathway. In July, the FDA wrote to food-industry leaders that transparency in food safety and nutrition actions was key to reducing illness. In September, the agency introduced Executive Incident Summary abstracts for closed outbreak investigations. Marler’s petitions build on that timeline, arguing that summaries should include more information about the companies and places involved.
The article also notes changes in FDA leadership. Marty Makary resigned in May 2026, and Kyle Diamantas has served as acting commissioner, according to the supplied text. It says President Donald Trump nominated Heidi Overton in August. The excerpt does not establish the status of that nomination or describe any subsequent leadership changes.
“The names are protected by the Trade Secrets Act.”
— The FDA, in its response to a February petition by Stop Foodborne Illness, as described by Marler
Petition Details and FDA Response
The supplied report is cut off during its account of an October chicken-wrap outbreak, so it does not show the complete description of either citizen petition. It also does not include copies of the petitions, their filing dates, the precise disclosures requested, or the legal explanation Marler says resolves the Trade Secrets Act question.
The excerpt gives no FDA response to the two petitions and does not say whether the agency has accepted, rejected, or begun reviewing them. It also does not establish whether company identities or geographic details were withheld in every example for the same reason. Those points should not be treated as settled based on Marler’s commentary alone.
FDA Review and Public Disclosures
The next confirmed milestone would be an FDA acknowledgment or response to the petitions, including any explanation of whether the agency can release company names and location information in closed or ongoing investigations. The supplied material does not give a response deadline or say when a decision is expected.
Readers should also look for the complete petition texts and any agency records clarifying the legal basis for withholding identifying information. Until those are available, the central development is Marler’s request and his case for broader disclosure—not a confirmed change in FDA policy.
Key Questions
What is Bill Marler asking the FDA to do?
Marler says two citizen petitions seek more identifying information in food-safety outbreak disclosures, particularly company names and location details. The supplied excerpt does not contain the complete petitions or their exact requested language.
Has the FDA agreed to release the information?
The source excerpt does not report an FDA decision or response to these two petitions. It describes an earlier agency response to a separate Stop Foodborne Illness petition, in which the FDA cited the Trade Secrets Act.
Why does identifying a company matter?
Company and location details can help consumers identify products or sources connected to an outbreak and support efforts to trace contaminated food. The petitions raise the question of how much detail the FDA can disclose while an investigation is underway or after it closes.
What information is still missing?
The supplied report ends before it gives the full requests, Marler’s explanation of the legal issue, or the FDA’s response. The status and review timeline of the petitions are also not stated.
Source: foodsafetynews.com
